GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

TD Cowen reiterated its Buy rating and $105.00 price target on Novo Nordisk (NYSE: NVO) Wednesday following meetings with the company’s senior leadership in Copenhagen. The pharmaceutical giant, with ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose weight more effectively and stay on track with its flagship medication, Wegovy ...

The global diabetic retinopathy market has shown a consistent growth in recent years and is expected to continue for the coming several years. According to a report from Grand View Research said that ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Detailed price information for Avant Technologies Inc (AVAI) from The Globe and Mail including charting and trades.

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...